Home >Markets >Stock Markets >AstraZeneca Pharma plunges over 13% on covid vaccine study pause
AstraZeneca’s COVID-19 vaccine-- AZD1222--uses an adenovirus that carries a gene for one of the proteins in SARS-CoV-2, the virus which causes COVID-19. (REUTERS)
AstraZeneca’s COVID-19 vaccine-- AZD1222--uses an adenovirus that carries a gene for one of the proteins in SARS-CoV-2, the virus which causes COVID-19. (REUTERS)

AstraZeneca Pharma plunges over 13% on covid vaccine study pause

  • On the BSE, the Astrazeneca stock tanks 13.40% to Rs3,650; and on the NSE, 12.31% to Rs3,710
  • AstraZeneca Plc has paused late-stage trials of its COVID-19 vaccine candidate developed with the University of Oxford

NEW DELHI : Shares of Astrazeneca Pharma India Ltd on Wednesday tumbled more than 13% after its parent firm announced pausing COVID-19 vaccine trials globally due to an unexplained illness in a study participant.

On the BSE, the Astrazeneca stock fell 13.40% to Rs3,650; and on the NSE, it tanked 12.31% to Rs3,710.

Late on Tuesday, AstraZeneca Plc said it was pausing late-stage trials of its COVID-19 vaccine candidate developed with the University of Oxford.

According to a New York Times report, a participant based in the United Kingdom was found to have transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections.

The COVID-19 vaccine was widely seen as one of the leading vaccine candidates against the novel coronavirus.

By 1:35 pm, shares of Astrazeneca Pharma India Ltd were trading at Rs3,956.90 apiece, down 6.12%, on the BSE; and at Rs3,945.90 apiece, 6.74% lower, on the NSE.

Tracking a deepening sell-off on global stock markets, the Indian shares also fell on Wednesday.

The BSE Sensex index was trading at 38,161.37, down 0.53%; and the Nifty 50 index, 0.56% lower, at 11,254.50.

The British drugmaker is working to expedite the review of the single event to minimise any potential impact on the trial timeline.

AstraZeneca’s COVID-19 vaccine-- AZD1222--uses an adenovirus that carries a gene for one of the proteins in SARS-CoV-2, the virus which causes COVID-19. The adenovirus is designed to induce the immune system for a protective response against SARS-CoV-2.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
x
×
My Reads Redeem a Gift Card Logout